Trial reportEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery2025
Phase 2 Dose-Ranging Trial of VGT-309 for Molecular Imaging of Cancer during Pulmonary Resection.
Trial report in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A single-chip, dual-gain color-NIR camera for fluorescence-guided lung and breast cancer surgery.Light, science & applications · 2026Article
- Phase II Multicenter Clinical Trial of Intraoperative Molecular Imaging with Abenacianine During Lung Cancer Surgery.Annals of surgical oncology · 2026Article
- Intraoperative Molecular Imaging in Thoracic Oncology: Expanding the Observable Disease Space.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesVGT-309 (abenacianine) is being evaluated as an intraoperative molecular imaging (IMI) agent. This phase 2, open-label, dose-ranging study evaluated efficacy and safety in participants undergoing surgical resection of suspicious or proven cancer in the lung.
methodsAdults who consented to participate in the study were assigned to treatment with VGT-309 at 0.05, 0.16, or 0.32 mg/kg dose administered 2-6 or 12-36 hours presurgery. Intraoperative tumour fluorescence intensity and contrast were assessed to inform efficacy across dosing parameter. Ex vivo imaging of surgical specimens was performed before and after histopathology.
resultsTwenty-seven participants received VGT-309. No lesions were visualized in participants receiving 0.05 mg/kg or 0.16 mg/kg administered 2-6 hours presurgery. Near-infrared (NIR) imaging after treatment with 0.16 mg/kg 12-36 hours presurgery identified 3 of 4 lesions from 3 of 4 participants. Sixteen participants were administered 0.32 mg/kg; 6 dosed 2-6 hours and 10 dosed 12-36 hours presurgery. IMI identified 6 of 7 lesions from 5 of 6 participants dosed 2-6 hours presurgery, while 8 of 11 lesions from 7 of 10 participants dosed 12-36 hours presurgery displayed intraoperative fluorescence. A single suspected unexpected serious adverse reaction of liver transaminitis resolved within 30 days. Otherwise, VGT-309 was safe and well tolerated in this study.
conclusionsResults support the safety and efficacy of VGT-309 in identifying cancer in the lung with 0.16 mg/kg day-before surgery dosing and 0.32 mg/kg at either dosing schedule. CLINICAL TRIAL REGISTRATION NUMBER: ACTRN12621000301864.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.